Anatomise Biostats

Executive Summary

Anatomise Biostats is a London-based consultancy specializing in biostatistics and data science for med-tech startups and SMEs. Founded in 2015, the company bridges the gap between clinical data and regulatory approval by offering expertise in trial design, statistical analysis, and compliance reporting. With the med-tech sector increasingly relying on data-driven insights and AI, Anatomise is well-positioned to capture growing demand. However, as a private consultancy without disclosed financials or major partnerships, its growth trajectory remains uncertain. The company's focus on biologics and diagnostics aligns with high-growth areas, but scalability is a key risk. Overall, Anatomise represents a niche opportunity in the expanding clinical data services market, though its lack of proprietary technology limits upside potential.

Upcoming Catalysts (preview)

• Q3 2026Major Contract with Top Med-Tech Firm40% success
• Q4 2026Launch of Proprietary AI Analytics Platform30% success
• Q2 2027First FDA Approval for Client Device20% success